The smad binding protein 1 gene (SMADIP1, MIM 605802) has been recently identified as a disease causing gene in a polytopic embryonic defect (MIM 235730) including midline anomalies, facial dysmorphic features and enteric nervous system malformation (Hirschsprung disease). To confirm the pleiotropic role of SMADIP1 during embryogenesis and investigate its role in neural crest cell derivatives differentiation, we performed RNA in situ hybridization at early stages of human development. According to the spectrum of malformations observed in patients, expression of SMADIP1 is observed in neural crest derived cells (peripheric nervous system, enteric nervous system, facial neurectoderm and cranial nerve ganglia), central nervous system, genital tubercle, muscles and kidneys. Surprisingly, SMADIP1 expression is also found in limbs and developing eye. Although congenital heart defects are frequently observed in patients with either a SMADIP1 large scale deletion or truncating mutation, no SMADIP1 expression could be detected in the developing heart at the stages studied. q
Results and discussion
Hirschsprung disease is a common malformation of neural crest derived enteric neurons and is frequently associated with other congenital abnormalities . Very recently, a novel recognizable syndrome has been associated with SMADIP1 gene haploinsufficiency (Lurie et al., 1994; Mowat et al., 1998; Cacheux et al., 2001; Wakamatsu et al., 2001; Yamada et al., 2001) . The Smad signaling pathway is critical in transmitting the transforming growth factor-beta (TGF-b) signal from the cell surface to the nucleus and for the regulation of transcriptional responses (Massagué and Wotton, 2000) . SMADIP1 is a member of the twohanded zinc finger/homeodomain family that acts as a transcriptional co-repressor of receptor-activated smad target genes and has been shown to play a proneuronal role in Xenopus (Remacle et al., 1999; Verschueren et al., 1999; Eisaki et al., 2000; Postigo and Dean, 2000) . Table 1 summarizes SMADIP1 gene expression observed in human embryos as well as clinical features reported in patients with SMADIP1 haploinsufficiency. No SMADIP1 expression is detected at day 26 of development (data not shown). By day 33, SMADIP1 is homogeneously expressed throughout the central nervous system from the mesencephalon to the spinal cord (Fig. 1 ). In the peripheral nervous system, SMADIP1 is expressed in the cranial nerve ganglia, spinal ganglia and sympathetic ganglia. A signal is also detected in limb buds. At day 37 of development, its expression is observed in the enteric nervous system, lung buds mesenchyme, the proximal nervous plexuses of the limb buds and the myotome. At day 47, SMADIP1 is expressed in the central nervous system from the pituitary stalk to the spinal cord. Interestingly, specific SMADIP1 expression is observed in the rhombencephalon, facial neurectoderm, mainly in the developing eyelids, the mandible and the middle ear region surrounding the developing ossicles. In the eye, a strong signal is seen in the anterior epithelium of the lens and the neural retina. This observation raises concern about the visual late outcome in these patients. SMADIP1 mRNAs are also detected in the outer layer of the stomach mesenchyme, the mesogastrum, around the mesonephros, and weakly but homogeneously in the adrenal glands. In the metanephros, expressing cells are located in Expressing cells are also detected in differentiating muscles. Conversely, SMADIP1 expression is not detected in the sclerotome and membranous bones. The study of 9-week old fetuses confirmed the expression of SMADIP1 in the mesenchyme of metanephros and the neural retina and choroid (Fig. 2) . At 15 weeks of development expression was confirmed in the enteric ganglia and submucose of oesophagus, intestine and colon as well as pulmonary mesenchyme. However, in the present study we were not able to confirm SMADIP1 expression observed in fetal and adult heart and great vessels (Cacheux et al., 2001; Yamada et al., 2001 ). According to this, a late onset expression is compatible with the congenital heart defects observed in patients. However, the question of a contiguous gene syndrome in patients with a SMADIP1 large scale deletion could be raised due to a higher frequency of congenital cardiac defect in those patients as compared to patients with a SMADIP1 truncating mutation (5/6 and 5/17, respectively, Table 1 ).
Materials and methods
Human embryos and fetal tissues were collected from legally terminated pregnancies in agreement with the French law and Ethics Committee recommendations. Tissues were prepared as previously described (Odent et al., 1999) . A 348-bp PCR fragment encoding SMADIP1 exon 6 and 131 bp of intronic sequence was amplified from human genomic DNA with primers F5 0 -GCTGC-CATTGATTTACTG-3 0 and R5 0 -GCCAATCAAAGCAA-TATCG-3 0 . A T7 extension (TAATACGACTCACTA-TAGGGAGA) was added to both primers to generate the antisense probe and the control sense probe, respectively. Probes were a[ 35 S]UTP labeled and purified as described previously (Odent et al., 1999) . Hybridization and posthybridization washes were carried out according to standard protocols (Wilkinson, 1992) . Slides were dehydrated, exposed to BIOMAX MR X-ray films (Amerscham) for 3 days, dipped in Kodak NTB2 emulsion for 3 weeks at 148C. Developed and toluidine blue counterstained slides were analyzed with dark and bright field illumination. No hybridization signal was detected with the a[ c Pes planus, pes valgus. d Vesicoureteral reflux (2), ureteric stenosis (1). e Persistent ductus arteriosus (6), atrial septal defect (3), ventricular septal defect (3), aortic coarctation (1), pulmonary stenosis (1). Several patients present a combination of heart defects. Five patients have a SMADIP1 large scale deletion and 5 patients a SMADIP1 truncating mutation. 
